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Below are some examples of the program components

Warfarin has been a mainstay of therapy for treatment and prevention of venous
thromboembolic disease (VTED) and prevention of stroke and systemic embolism
for over 50 years. Recent FDA approval of several novel oral anticoagulants has
offered more extensive treatment options for management of these disease states.

Dabigatran Inclusion and Exclusion Criteria

100

Approved by P&T Committee and Medical Executive Committee Spring
2011

Novel Anticoagulant

FDA Approval Date

Approved Indication

Dabigatran

October 19, 2010

Prevention of stroke and
systemic embolism

New inpatient requests for dabigatran should be screened for appropriateness
of use. Use of dabigatran not meeting inclusion criteria would require a
consult from Cardiology, Vascular Medicine (JATS), or Cardeza to approve
use in the inpatient setting.

Percentage of Novel Anticoagulant Orders
Requiring Intervention

80
60

Dabigatran

40

Rivaroxaban

20

Rivaroxaban

0

Rivaroxaban

November 4, 2011

Prevention of stroke and
systemic embolism

A. Inclusion criteria:

Apixaban

November 2, 2012

Treatment acute and chronic VTED

December 28, 2012

Prevention of stroke and
systemic embolism

Prevention of stroke and systemic embolism in patients with non-valvular
atrial fibrillation

Dabigatran Surveillance Program (2 year period)

B. Exclusion criteria:

93% of all orders required an intervention

Patients with atrial fibrillation and history of mitral valve stenosis,
valvuloplasty or rheumatic heart disease.

Average patient age: 73 yrs.		

The availability of the novel anticoagulants offers an attractive alternative to warfarin
therapy for patients due to their convenience of use. In comparison to warfarin,
dabigatran, rivaroxaban and apixaban offer:
-

a fixed dosage regimen

-

a relatively small potential drug interaction profile

-

minimal laboratory monitoring

-

little to no dietary restrictions.

Although these agents offer a relatively fixed dose regimen, dosage adjustment is
required in moderate renal dysfunction, and use is contraindicated in severe renal
dysfunction. Currently there are no specific reversal agents in the event of a novel anticoagulant associated bleed. These concerns led to the development of an
anticoagulation stewardship program at our institution to monitor and guide the
usage of these agents.

Background of the Program:
Thomas Jefferson University Hospital is a 957 licensed acute care bed
academic medical center with 3 hospital locations in the Philadelphia
area, including a facility in center city, South Philadelphia and a neuroscience hospital. Our neuroscience hospital, JHN, is the only hospital
dedicated to the treatment of neurological diseases in the Philadelphia
region, and receives a large number of transfers from hospitals within the
tri-state area for management of intracranial hemorrhages, including
those associated with anticoagulation use.
In an effort to insure the safe and appropriate use of the novel
anticoagulants and timely management of admissions from the
community for associated adverse events, a steering committee of
specialized physicians and pharmacists met to develop a comprehensive
management program, which includes:
- guidelines for use
- an educational program
- CPOE order sets
- a surveillance program
-monitoring criteria with recommended laboratory assays
- perioperative management guidelines
- emergency management response process
A care transitions program was also developed to insure proper
communication of care plans and follow-up after discharge, and to,
hopefully, prevent adverse events and readmissions.

Infectious endocarditis
Patients with a previous stroke within the past 6 months

Hospital Novel Anticoagulant Emergency
Management Team

Major surgery within the past month

•

History of intracranial, intraocular, spinal, retroperitoneal,
gastrointestinal or atraumatic intra-articular bleeding

•

History of a hemorrhagic disorder, including hemophilia

•

Active malignancies of a highly vascular nature

Average patient weight: 83 kg

Age Range 35 – 90 yrs.

Weight Range: 40 – 179 kg

Majority of interventions required in the “frail elderly” population
Frequent interventions included: switching to a more appropriate anticoagulant due to poor
renal function, dosage adjustment and discontinuation of duplicate anticoagulants: e.g.
subcutaneous heparin ordered for “DVT prophylaxis” with dabigatran.

Conditions associated with an increased risk of bleeding, including, but not
limited to:
•

Dabigatran

Rivaroxaban Intervention by Type (%) N=67
Inappropriate
Agent

Inappropriate Dose

Other

Symptomatic or endoscopically documented gastroduodenal ulcer, Crohn’s
disease, ulcerative colitis or severe GERD

Contraindication
Requiring D/C

Pt unable to swallow an intact pill, such as patients with an enteral feeding
tube

Duplicate Anticoagulants
Significant Drug Interaction

Uncontrolled hypertension (systolic blood pressure >180 mm Hg and/or diastolic blood pressure > 100 mm Hg)

Drug Information

As part of an ongoing quality and safety initiative, bleeding events
associated with novel anticoagulant use are being monitored in
hospitalized patients at our institution. All hemorrhagic events occurred
within the community and resulted in an admission to our hospital
system, mainly at our neuroscience hospital. A summary of these adverse
events and cost of care is listed below:

Summary of Adverse Events and Patient Characteristics
8 patients were admitted to TJUH from November 2011 to May 2012
for bleeding, all were associated with dabigatran use. Six patients were
transferred from an outside hospital to our neuroscience hospital for
ICH management. All patients were on anticoagulation for atrial
fibrillation, the most commonly prescribed dose of dabigatran was 150mg
BID. Average pt age was 80.3 yrs. (range 63-90).
Average admission serum creatinine was 1.8 mg/dL (range 0.5-3.0).
Female to Male 1:1. Strategies for the management of bleeding included
withholding dabigatran, supportive care, administration of blood
products and hemodialysis, when required. Dialysis was initiated on 3
patients, conventional +/ - CVVHD.
One patient died.
The average aPTT on admission was 69 seconds (range 32-170).
The average ICU length of stay was 10.4 days (range 0-39), with an
average ICU cost of $28,883.75. Total inpatient cost averaged
$46,603.00m with a cost range of $15,963.00 – 160,899.00. The
average length of stay was 14 days (range 5-44).
Patient
Case

1

Age &
Gender

Scr
(mg/dl)

Dabigatran
Dose

Type of
Bleed

aPTT at
baseline
(secs)

76 M

1.1

150 mg BID

GU

85

Time to Length
normalize
of
aPTT
Stay
Remained
elevated

5

ICU L
OS

Factor
Products /RX
Received

Co-Morbidities

Other
Outpatient
Meds on
Admission

1

FFP
Supportive

Afib
COPD
HTN
low-grade
B lymphoma
glaucoma

Amiodarone
Digoxin
Diltiazem
Tamsulosin
prn:
Levalbuterol
Ipratropium
Advair

Pharmacokinetic Consult
Required

Patient Noncompliance Issues

Severe renal dysfunction (i.e. CrCl < 30 ml/min) or unstable renal function
with declining urine output (<0.5 ml/kg/hr based on ideal body weight) in a
patient with a baseline CrCl < 50 ml/min

Adverse Events

Inappropriate Lab Assay
Ordered
Lab Assay
Order Required

Rivaroxaban Surveillance Program (1 year period)

2

79 M

3.1

75 mg BID

ICH

54

7 days

11

8

Hemodialysis,
Supportive

HTN
CAD
CHF
COPD

Amlodipine
Flecainide
Omeprazole

3

84 F

0.7

150 mg BID

ICH

60

4 days

17

9

Supportive

Parox Afib
CAD
HTN
RA
urticarial
vasculitis

Amiodarone
Duloxetine
Famotidine
Furosemide
Hydrocortisone.
Levetiracetam
Metoprolol
Multivitamin
Mycophenolate
Senna

68 % of all orders required an intervention

Age < 18 years of age
Pregnant or nursing mothers
Active liver disease, including ALT, AST, Alk Phos > two times upper normal
limits, active Hepatitis A,B,C

Average patient age: 61 yrs.		

Age Range 15 – 91 yrs.

Average patient weight: 82 kg 		

Weight Range: 36 – 157 kg

Majority of interventions required in the “frail elderly” population, requiring conversion to
a more appropriate anticoagulant due to unstable and / or declining renal function, often in
the setting of advanced CHF. Alteration in concomitant medication regimens required for
contraindicated medications, including carbamazepine use in a patient being treated with
rivaroxaban for a Saddle Pulmonary Embolism.

Clinically significant anemia (Hgb < 10g/dl)
Thrombocytopenia (platelet count < 100 X 103/L)

4

87 F

3.9

150 mg BID

GI and
epistaxis

170

March 1st
2012

5

4

2 units PRBC,
Supportive

Acute
renal failure
Afib CAD
HTN
Hyperlipidemia
COPD

Aspirin 81
mg daily
Bumetanide
Lovastatin
Metolazone
Metoprolol
Olmesartan
Tiotropium

5

80F

0.9

150 mg BID

ICH/SAH

60

2 days

8

4

Hemodialysis
X 2 sessions,
Supportive

Afib
CAD
HTN
Hx:
Breast CA
Melanoma
Bilateral
carotid
stenosis

Aspirin 81
mg daily
Celecoxib
Diltiazem ER
HCTZ
Lisinopril
Metaxalone
Vytorin®

Cardiomypathy
Severe AS
Afib
Outcome:
Pt died

Amiodarone
Carvedilol
Furosemide
Lisinopril
Omeprazole

Anemia
Afib
CAD
CRI, stage IV
Depression
GERD
HTN
Hyperlipidemia
PSVT

Digoxin
Dronedarone
Escitalopram
Metoprolol
Mirtazepine

Acute
renal failure
Aflutter
CAD
COPD
V tach

Aspirin 81
mg daily
Clopidogrel

Known history of non-compliance
No prescription coverage or means to acquire medication

Dabigatran Orders Requiring Intervention by Type (%)
N=71

Concomitant use of Rifampin
C. Relative Contraindications
o

Advanced age > 75 years of age

o
		
		

Caution should be exercised in certain high risk populations,
such as combined advanced age (>75 years), with low body
weight and / or renal dysfunction (CrCl < 50 ml/min)

o
		

Concomitant antiplatelet therapy: prasugrel, clopidogrel,
aspirin or NSAIDS

o
Pt requiring ongoing repeat interruption of therapy for
		
invasive procedures, e.g. patient with ascites requiring repeat
		paracentesis procedures
o
Concomitant therapy with other drugs known to be major
		
p-glycoprotein inducers or inhibitors, e.g. amiodarone,
		quinidine
o

Prior history of MI or unstable angina

Our Experience

Lab Assay Order Required
Inappropriate Lab Assay Ordered
Pharmacokinetic Consult Required
Significant Drug Interaction

Drug Information
Other
Inappropriate
Agent

Impact of Community Prescribing on Our Institution:

6

83 M

1.5

150 mg BID

SDH,
cardiogenic
shock

32

N/A

4

4

Supportive:
Pressors,
Intubation

7

90 F

0.9

150 mg BID

SAH. SDH

39

N/A

18

15

Hemodialysis,
Supportive

8

63 M

2.8

150 mg BID

GI / retroperitoneal

48

2 days

44

39

Hemodialysis:
CVVHD,
Supportive,
Pressors

Duplicate
Anticoagulants

The use of dabigatran, rivaroxaban and apixaban has resulted in increased
workload on our pharmacy team to insure safe and appropriate
utilization of these agents. The majority of interventions has occurred at
time of admission, and mainly has involved either: suboptimal patient
selection, dosing or inappropriate management in the perioperative
period. A summary of the interventions are listed below.

Contraindication
Requiring D/C
Inappropriate Dose

Apixaban Surveillance Program: Implementation pending official approval for
formulary addition

Cost in Dollars

Introduction:

Novel Anticoagulation Stewardship Program

Patients

Total Cost of Care
As expected, the inpatient cost for caring for patients admitted with a
novel anticoagulant associated bleeding event was high, with the highest
costs incurred in patients admitted with an intracranial hemorrhage and
those requiring hemodialysis for emergency management.
Average Total Cost of Care

Total Cost of Care Range

$46,603.00

$15,963.00 – 160,899.00

Conclusions:
The perceived ease of use of the novel anticoagulants has resulted in an
increasingly popular utilization of these agents in the outpatient
population as an alternative to warfarin therapy. These agents are
frequently employed in the elderly population, since it is often difficult
for this group of patients to go to their doctor’s office or a laboratory for
the required laboratory testing needed with warfarin management,
mainly due to transportation and health issues.
These anticoagulants must be used with caution in certain subsets of
patients, including the frail elderly or those with comorbidities which
increase the risk for unstable and declining renal function. We have found
that development and implementation of screening and educational tools
were very useful in insuring appropriate patient selection by providing
ongoing education to the house staff; we have experienced relatively little
problems with new inpatient orders for these agents. Most of our efforts
have involved adjustment and alteration of orders at the time of
admission for patients chronically prescribed novel anticoagulants as
outpatient therapy.
Experience from our stewardship program has shown that many orders
from the community require alteration to another more optimal
anticoagulant agent or adjustment of dose due to factors that increase the
risk for drug accumulation and development of adverse events.
Novel anticoagulant adverse events can be difficult to manage and result
in long ICU stays and high healthcare costs. Widespread use within the
community has lead to increased workload on our pharmacy and
medical staff to assess and adjust inappropriate usage. A formalized
transition of care program is necessary to: insure appropriate monitoring
and follow up after discharge, insure adequate communication of care
plans to outpatient physicians, enhance patient understanding and compliance with treatment / follow-up, and insure optimal patient outcomes.

